March 01, 2023

First 1-Day Lens that Combines Innovative DigitalBoost™ & Aquaform® Technologies
Designed to Deliver Extraordinary Comfort for Patients’ ‘Always On’ Digital Lifestyles

SAN RAMON, Calif., March 1, 2023—Signaling a new advancement in addressing symptoms associated with digital device use, CooperVision® MyDay Energys® contact lenses are now available to all eye care professionals across the United States. The nationwide rollout marks the global debut of the highly innovative lens.

In a clinical study, patients agreed that when wearing MyDay Energys®, their eyes stay comfortable and relaxed throughout the day, despite frequently viewing digital devices.**1 The wearers also agreed that MyDay Energys® made their eyes feel less tired, and their vision was less blurry.1

MyDay Energys® is the first and only 1-day contact lens combining a CooperVision-exclusive aspheric design and material technology to help tiredness and dryness associated with digital device use, providing extraordinary comfort**1. The precisely-engineered DigitalBoost single vision aspheric design delivers a +0.3D boost of power, intended to ease strain on eye muscles so the wearer can shift focus from on screen to off screen with less effort.*2 CooperVision also incorporated its popular Aquaform® Technology, which hydrates MyDay Energys® lenses to twice their weight in water3 for natural wettability and incredible comfort, helping eyes feel less dry, even during times of reduced blinking.

“The average American now spends more than seven hours per day looking at screens,4 with more than half using two or more devices simultaneously.5 Our ability to anticipate this evolution of digital usage and increase in 1-day preference allowed us to be first to market with such an inventive lens,” said Michele Andrews, OD, Vice President, Professional and Government Affairs, Americas, CooperVision. “Based on enthusiastic feedback from trial customers, we expect U.S. eye care professionals and contact-lens wearers to widely embrace MyDay Energys®.”

MyDay Energys® is the newest addition to CooperVision’s popular MyDay® family, which includes MyDay® sphere, MyDay® toric, and MyDay® multifocal contact lenses. MyDay Energys® is available in sphere powers of +8.00D to -12.00D (0.50D steps after +5.00D and -6.00D), with no plano option. MyDay Energys® also includes built-in UV blocking (86% of UVA and 97% of UVB rays), helping to minimize the transmission of harmful UV rays ҂.

“With the MyDay® portfolio, you can fit so many patients between the sphere, the expanded toric parameters, and the multifocal,” said Sahil Dosaj, OD, who practices at Miller Optometry in Yucaipa, Calif. “Now, MyDay Energys® is another option with additional benefits we can offer our patients. Everyone uses digital devices, so with many sphere wearers—this is the lens for them.”

For more information, visit the MyDay Energys® practitioner page.



*Based on a statistically significant difference of the mean change in Accommodative Microfluctuations and when compared to a lens without DigitalBoost™ /Digital Zone Optics® after reading on an iPhone 5 for 20 minutes held at a distance of 25 cm. Study conducted with Biofinity Energys and sphere.

**75% of patients slightly agree/agree/strongly agree

†80% of patients agreed when asked "CLs make my eyes feel less tired"

‡74% of patients agreed when asked "CLs make my vision less blurry end of day, even after a long day using digital devices"

҂Warning: UV-absorbing contact lenses are not substitutes for protective UV-absorbing eyewear, such as UV-absorbing goggles or sunglasses, because they do not completely cover the eye and surrounding area. Patients should continue to use UV-absorbing eyewear as directed.

1. CVI data on file 2018. Prospective, multi-center (5 US sites), open label, bilateral wear, one week dispensing study with MyDay Energys. N=77 habitual soft CL wearers. Patients slightly agree/agree/strongly agree.

2. Kajita M et al. Changes in accommodative micro-fluctuations after wearing contact lenses of different optical designs. Cont Lens Ant Eye (2020) In Press

3. CVI data on file 2022.

4. Digital 2023: The United States of America. Datareportal. Consumption of different digital media types may occur concurrently. Accessed 9 February 2023.

5. Vision Council 2019. The Vision Council shines light on protecting sight and health in a multiscreen era. Accessed 19 July 2022.



About CooperVision 
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit

About CooperCompanies 
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 14,000 with products sold in over 100 countries. For more information, please visit

Forward-Looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding a product launch and anticipated demand for new products. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to research and development, regulatory requirements, clinical studies, sales, marketing, and distribution plans and capabilities; potential product performance and quality issues; intellectual property risks; competition; and other factors described in CooperCompanies’ Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper’s Annual Report on Form 10-K for the fiscal year ended October 31, 2022, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company’s analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.

Media Contact
Heather Kowalczyk, APR
McDougall Communications for CooperVision
(585) 434-2148 or